OCUL – Ocular Therapeutix, Inc.
Float Short %
6.03
Margin Of Safety %
Put/Call OI Ratio
1.04
EPS Next Q Diff
EPS Last/This Y
0.15
EPS This/Next Y
0.04
Price
7.78
Target Price
25.54
Analyst Recom
1.08
Performance Q
-33.84
Upside
-507.2%
Beta
0.94
Ticker: OCUL
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | OCUL | 10.26 | 1.21 | 0.54 | 127390 |
| 2026-01-26 | OCUL | 10.9 | 1.22 | 2.44 | 145884 |
| 2026-01-27 | OCUL | 10.84 | 1.26 | 0.86 | 157290 |
| 2026-01-28 | OCUL | 10.27 | 1.22 | 0.72 | 159534 |
| 2026-01-29 | OCUL | 9.95 | 1.20 | 0.64 | 163006 |
| 2026-01-30 | OCUL | 9.13 | 1.19 | 0.68 | 164545 |
| 2026-02-02 | OCUL | 9.14 | 1.18 | 0.10 | 170851 |
| 2026-02-03 | OCUL | 8.51 | 1.11 | 0.27 | 179598 |
| 2026-02-05 | OCUL | 8.92 | 1.07 | 1.59 | 190033 |
| 2026-02-09 | OCUL | 9.43 | 0.97 | 1.35 | 198296 |
| 2026-02-10 | OCUL | 9.02 | 0.98 | 2.31 | 205194 |
| 2026-02-11 | OCUL | 9.16 | 1.07 | 2.33 | 226288 |
| 2026-02-12 | OCUL | 9.05 | 1.09 | 3.44 | 231585 |
| 2026-02-13 | OCUL | 8.88 | 1.17 | 2.05 | 241756 |
| 2026-02-17 | OCUL | 6.99 | 1.19 | 1.65 | 245078 |
| 2026-02-18 | OCUL | 6.88 | 1.14 | 0.24 | 244270 |
| 2026-02-19 | OCUL | 7.02 | 1.09 | 0.32 | 246884 |
| 2026-02-20 | OCUL | 7.79 | 1.04 | 0.55 | 243624 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | OCUL | 10.28 | -16.1 | - | -1.43 |
| 2026-01-26 | OCUL | 10.91 | -16.1 | - | -1.43 |
| 2026-01-27 | OCUL | 10.84 | -16.1 | - | -1.43 |
| 2026-01-28 | OCUL | 10.30 | -16.1 | - | -1.43 |
| 2026-01-29 | OCUL | 9.95 | -16.1 | - | -1.43 |
| 2026-01-30 | OCUL | 9.14 | -16.1 | - | -1.43 |
| 2026-02-02 | OCUL | 9.14 | -16.1 | - | -1.43 |
| 2026-02-03 | OCUL | 8.52 | -16.1 | - | -1.43 |
| 2026-02-04 | OCUL | 8.56 | -16.1 | - | -1.43 |
| 2026-02-05 | OCUL | 8.92 | -16.1 | - | -1.43 |
| 2026-02-06 | OCUL | 9.17 | -16.1 | - | -1.43 |
| 2026-02-09 | OCUL | 9.44 | -16.1 | - | -1.43 |
| 2026-02-10 | OCUL | 9.03 | 18.1 | - | -1.31 |
| 2026-02-11 | OCUL | 9.16 | 16.8 | - | -1.30 |
| 2026-02-12 | OCUL | 9.04 | 16.8 | - | -1.30 |
| 2026-02-13 | OCUL | 8.88 | 16.8 | - | -1.30 |
| 2026-02-17 | OCUL | 6.99 | 16.8 | - | -1.30 |
| 2026-02-18 | OCUL | 6.88 | 16.8 | - | -1.30 |
| 2026-02-19 | OCUL | 7.03 | 19.4 | - | -1.27 |
| 2026-02-20 | OCUL | 7.78 | 19.4 | - | -1.27 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | OCUL | -0.43 | 19.45 | 6.63 |
| 2026-01-26 | OCUL | -0.43 | 19.46 | 6.63 |
| 2026-01-27 | OCUL | -0.43 | 19.46 | 6.63 |
| 2026-01-28 | OCUL | -0.43 | 19.46 | 6.87 |
| 2026-01-29 | OCUL | -0.43 | 19.46 | 6.87 |
| 2026-01-30 | OCUL | -0.43 | 19.46 | 6.87 |
| 2026-02-02 | OCUL | -0.43 | 19.50 | 6.87 |
| 2026-02-03 | OCUL | -0.43 | 19.50 | 6.87 |
| 2026-02-04 | OCUL | -0.43 | 19.50 | 6.87 |
| 2026-02-05 | OCUL | -0.47 | 19.50 | 6.87 |
| 2026-02-06 | OCUL | -0.47 | 19.50 | 6.87 |
| 2026-02-09 | OCUL | -0.46 | 20.78 | 6.72 |
| 2026-02-10 | OCUL | -0.46 | 20.78 | 6.72 |
| 2026-02-11 | OCUL | -0.46 | 20.78 | 6.05 |
| 2026-02-12 | OCUL | -0.46 | 20.78 | 6.05 |
| 2026-02-13 | OCUL | -0.46 | 20.78 | 6.05 |
| 2026-02-17 | OCUL | -0.46 | 24.51 | 6.04 |
| 2026-02-18 | OCUL | -1.02 | 24.51 | 6.04 |
| 2026-02-19 | OCUL | -1.02 | 24.51 | 6.04 |
| 2026-02-20 | OCUL | -1.02 | 24.51 | 6.03 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.3
Avg. EPS Est. Next Quarter
-0.31
Insider Transactions
-1.02
Institutional Transactions
24.51
Beta
0.94
Average Sales Estimate Current Quarter
12
Average Sales Estimate Next Quarter
13
Fair Value
Quality Score
42
Growth Score
38
Sentiment Score
2
Actual DrawDown %
63.8
Max Drawdown 5-Year %
-90
Target Price
25.54
P/E
Forward P/E
PEG
P/S
32.6
P/B
2.57
P/Free Cash Flow
EPS
-1.44
Average EPS Est. Cur. Y
-1.27
EPS Next Y. (Est.)
-1.23
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-511.9
Relative Volume
2.43
Return on Equity vs Sector %
-69.7
Return on Equity vs Industry %
-52.2
EPS 1 7Days Diff
EPS 1 30Days Diff
0.21
EBIT Estimation
Ocular Therapeutix, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 325
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
stock quote shares OCUL – Ocular Therapeutix, Inc. Stock Price stock today
news today OCUL – Ocular Therapeutix, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCUL – Ocular Therapeutix, Inc. yahoo finance google finance
stock history OCUL – Ocular Therapeutix, Inc. invest stock market
stock prices OCUL premarket after hours
ticker OCUL fair value insiders trading